(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 November 2015 (19.11.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/173267 A1

(51) International Patent Classification:
A61P 35/00 (2006.01) *C07K 16/28* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/EP2015/060523

(22) International Filing Date:
12 May 2015 (12.05.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/992,658	13 May 2014 (13.05.2014)	US
62/105,992	21 January 2015 (21.01.2015)	US
62/114,336	10 February 2015 (10.02.2015)	US

(71) Applicant: **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(72) Inventors: **NARWAL, Rajesh**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **ROBBINS, Paul**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **KARAKUNNEL, Joyson**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **DAR, Mohammed M.**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(74) Agent: **WINTER, Christopher, Spencer**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,

[Continued on next page]

(54) Title: ANTI-B7-H1 AND ANTI-CTLA-4 ANTIBODIES FOR TREATING NON-SMALL CELL LUNG CANCER

(57) Abstract: Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof and tremelimumab or an antigen- binding fragment thereof.

FIG. 1



WO 2015/173267 A1

SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*